HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers

This phase I study evaluated the feasibility of expanding HER-2/neu (HER2) vaccine-primed peripheral blood T-cells ex vivo and assessed the safety of T-cell infusions. Eight patients with HER2(+) treatment refractory metastatic cancers were enrolled. T-cells could be expanded to predefined parameter...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Disis, Mary L., Dang, Yushe, Coveler, Andrew L., Marzbani, Edmond, Kou, Zhong C., Childs, Jennifer S., Fintak, Patricia, Higgins, Doreen M., Reichow, Jessica, Waisman, James, Salazar, Lupe G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945106/
https://ncbi.nlm.nih.gov/pubmed/24162107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-013-1489-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares